Alzheimer's disease (AD) exists on a clinical and genetic spectrum encompassing both familial and sporadic forms. While both share the core pathological features of amyloid-beta (Abeta) plaques and neurofibrillary tangles (NFTs) composed of hyperphosphorylated tau, they differ substantially in their genetic architecture, age of onset, rate of progression, and therapeutic responses. Understanding these differences is critical for accurate diagnosis, genetic counseling, clinical trial design, and development of personalized therapeutic approaches.
Alzheimer's disease (AD) exists on a clinical and genetic spectrum encompassing both familial and sporadic forms. While both share the core pathological features of amyloid-beta (Abeta) plaques and neurofibrillary tangles (NFTs) composed of hyperphosphorylated tau, they differ substantially in their genetic architecture, age of onset, rate of progression, and therapeutic responses. Understanding these differences is critical for accurate diagnosis, genetic counseling, clinical trial design, and development of personalized therapeutic approaches.
Familial Alzheimer's disease (FAD) accounts for less than 5% of all AD cases and is caused by highly penetrant mutations in one of three genes: [APP](/genes/app), [PSEN1](/genes/psen1), or [PSEN2](/genes/psen2). These mutations lead to autosomal dominant inheritance with virtually complete penetrance and typically early onset (30-60 years) [@ryman2014].
Sporadic (late-onset) Alzheimer's disease (LOAD) accounts for over 95% of cases and is thought to arise from a complex interplay of multiple genetic risk variants (polygenic) combined with environmental and lifestyle factors. Age of onset is typically after 65 years, with incomplete penetrance [@scheltens2021].
| Feature | Familial AD | Sporadic (LOAD) AD |
|---------|-------------|--------------------|
| Proportion of all AD | <5% | >95% |
| Primary Genes | APP, PSEN1, PSEN2 | APOE, TREM2, ~80+ risk loci |
| Inheritance Pattern | Autosomal dominant | Polygenic, complex |
| Onset Age | 30-60 years (mean ~50) | >65 years (mean ~75) |
| Penetrance | >99% | ~40-50% by age 85 |
| Family History | Strong (multiple affected generations) | Variable (may be absent) |
| Causative vs Risk | Causative (pathogenic) | Risk alleles (modify susceptibility) |
| Mutation Type | Highly penetrant missense | Common variants (mostly non-coding) |
Gene Location: Chromosome 21q21.3
Inheritance: Autosomal dominant
Pathogenic Mechanism: Mutations increase Aβ production or aggregation tendency:
| Mutation | Effect | Onset Age | Notes |
|----------|--------|-----------|-------|
| Swedish (K670N/M671L) | Increased Aβ production | 50-60 years | First identified, mimics β-secretase cleavage |
| Flemish (A692G) | Increased Aβ production | 40-50 years | Higher Aβ40, cerebral hemorrhage |
| Arctic (E693G) | Enhanced protofibril formation | 50-60 years | Dutch, Flemish, Arctic mutations cluster |
| Dutch (E693Q) | Aβ aggregation | 50-60 years | Hereditary cerebral amyloid angiopathy |
| Austrian (T714I) | Increased Aβ42 | 50-55 years | Vienna mutation |
| Indiana (V715M) | Altered γ-secretase cleavage | 50-55 years | Increases Aβ42/40 ratio |
| Florida (I716V) | Increased Aβ42 | 50-55 years | Similar to Indiana |
| London (V717I) | Increased Aβ42 | 50-60 years | Most common APP mutation |
| Iberian (I716F) | Increased Aβ42 | 45-55 years | Spanish family |
Key References: Over 50 pathogenic APP mutations have been described. The APP duplication syndrome ( Down syndrome) leads to early-onset AD due to gene dosage effect.
Gene Location: Chromosome 14q24.3
Inheritance: Autosomal dominant
Pathogenic Mechanism: Mutations alter γ-secretase activity, increasing Aβ42/40 ratio:
| Mutation Class | Examples | Effect |
|---------------|----------|--------|
| Aβ42 increase | M146L, L286V, A246E | Shift toward Aβ42 production |
| Aβ generation | L435F, C410Y | Reduced total Aβ production |
| Protein folding | Many missense | Partial loss of function |
| Atypical | Large deletions | Complete loss of function (PCA) |
Phenotype Variations:
Gene Location: Chromosome 1q42.13
Inheritance: Autosomal dominant
Pathogenic Mechanism: Similar to PSEN1 but with lower penetrance and later onset:
| Mutation | Effect | Onset Age |
|----------|--------|-----------|
| N141I | Increased Aβ42 | 50-70 years |
| M239V | Increased Aβ42 | 55-75 years |
| T122P | Altered cleavage | 60-75 years |
| Various | Variable | 45-85 years |
Key Features:
Gene Location: Chromosome 19q13.32
Alleles and Effects:
| Allele | Frequency | AD Risk | Effect |
|--------|-----------|---------|--------|
| ε3/ε3 | ~60% | Baseline | Reference |
| ε3/ε4 | ~20% | 2-3x increased | 1 copy increases risk |
| ε4/ε4 | ~2% | 8-12x increased | Highest risk |
| ε2/ε3 | ~15% | Slightly decreased | Protective |
| ε2/ε4 | ~3% | No effect | ε2 neutralizes ε4 |
Mechanism: APOE ε4 affects:
Gene Location: Chromosome 6p21.1
Key Variants:
| Variant | Effect | Risk Ratio |
|---------|--------|------------|
| R47H | 2-4x increased | Strongest TREM2 risk |
| R62H | 1.5x increased | Moderate |
| Y402C | Age-related macular degeneration | Not for AD |
| L253P | 5x increased | Rare |
Mechanism: TREM2 is expressed on microglia and mediates:
Major LOAD Risk Loci (2022 Bellenguez et al.): [@bellenguez2022]
| Gene/Region | Function | Effect Size (OR) |
|-------------|----------|-----------------|
| APOE | Lipid metabolism | 2.5-4.0 |
| CLU | Complement system | 1.1-1.2 |
| PICALM | Endocytosis | 1.1-1.2 |
| CD33 | Immune receptor | 1.1-1.2 |
| MS4A4E | Cell surface | 1.1 |
| CR1 | Complement receptor | 1.1-1.2 |
| BIN1 | Bridging integrator | 1.1-1.2 |
| PTK2B | Tyrosine kinase | 1.1 |
| SORL1 | Sortilin receptor | 1.2-1.3 |
| ABCA7 | Lipid transport | 1.1-1.2 |
| EPHA1 | Ephrin receptor | 1.1 |
| HLA-DRB1 | MHC class II | 1.1 |
| NME8 | NMDP | 1.1 |
| ZCWPW1 | Chromatin | 1.1 |
| CELF1 | RNA binding | 1.1 |
Polygenic Risk Scores: Combining ~80+ risk variants can identify individuals with 3-4x elevated risk.
Distribution:
Distribution:
| Feature | Familial AD | Sporadic AD |
|---------|-------------|--------------|
| Mean onset | 45-50 years | 75 years |
| Range | 30-70 years | 60-95 years |
| Peak decade | 40s-50s | 70s-80s |
| APOE effect | Minimal | Major (ε4 lowers by ~10 years) |
| Family history | Required for diagnosis | May be absent |
| Predictability | High with known mutation | Variable |
Familial AD Progression:
Clinical Progression Stages:
| Stage | Familial AD | Sporadic AD |
|-------|-------------|--------------|
| Preclinical | 25-15 years before symptoms | 20-10 years before symptoms |
| MCI due to AD | 5-3 years before dementia | 5-3 years before dementia |
| Mild dementia | 2-4 years | 2-4 years |
| Moderate | 2-4 years | 2-6 years |
| Severe | 1-3 years | 2-4 years |
Cerebral Spinal Fluid (CSF) Biomarkers:
| Biomarker | Familial AD | Sporadic AD |
|-----------|-------------|--------------|
| Aβ42 | Decreases early (20+ years pre-symptom) | Decreases ~10-15 years pre-symptom |
| Total tau | Increases early | Increases later |
| p-tau181/217 | Increases ~10 years pre-symptom | Increases ~5 years pre-symptom |
| NfL | Increases closer to onset | Variable |
PET Imaging:
| Modality | Familial AD | Sporadic AD |
|----------|-------------|--------------|
| Amyloid PET | Positive 20+ years before onset | Positive 10-15 years before onset |
| Tau PET | Regional pattern ~5 years before | Regional pattern near onset |
| FDG-PET | Hypometabolism follows biomarker changes | Similar pattern but later |
Both FAD and LOAD show the classic AD lesions, but with differences:
| Feature | Familial AD | Sporadic AD |
|---------|-------------|--------------|
| Amyloid plaques | Dense, cored, early | Variable, diffuse early |
| NFT distribution | Similar Braak staging | Similar Braak staging |
| Aβ42/40 ratio | High (mutations increase Aβ42) | Lower, more variable |
| Cerebral amyloid angiopathy | Common (especially APP mutations) | Present in ~50% |
| Lewy bodies | Less common | More common (~50%) |
| Vascular pathology | Variable | Often significant |
FAD Pathology:
Familial AD Mechanisms:
| Biomarker | FAD | LOAD | Interpretation |
|-----------|-----|------|----------------|
| CSF Aβ42 | Very low (20+ years pre-symptom) | Low (10-15 years pre-symptom) | Both reflect amyloid |
| CSF Aβ40 | May be high (APP mutations) | Normal | APP mutations increase production |
| CSF total tau | High early | Increases later | Non-specific neuronal injury |
| CSF p-tau181 | High ~10 years pre-symptom | Increases near onset | Tau pathology |
| Plasma Aβ42/40 | Decreased | Decreased | Both show amyloid |
| Plasma p-tau217 | Increases early | Increases near onset | Both show tau |
| Plasma NfL | Increases near onset | Variable | Neuronal injury |
| Modality | FAD | LOAD |
|----------|-----|------|
| Amyloid PET | Positive early, high burden | Positive, moderate burden |
| Tau PET | Earlier spread pattern | Later spread pattern |
| MRI atrophy | Earlier, may be aggressive | Variable pattern |
| FDG-PET | Temporoparietal hypometabolism | Similar pattern |
| Feature | FAD | LOAD |
|---------|-----|------|
| A (Amyloid) | Positive earliest | Positive early |
| T (Tau) | Positive ~10 years pre-symptom | Positive ~5 years pre-symptom |
| N (Neurodegeneration) | Follows tau | Follows tau |
Anti-Amyloid Immunotherapies:
| Drug | Target | FAD Response | LOAD Response | Notes |
|------|--------|--------------|---------------|-------|
| Lecanemab | Aβ protofibrils | May benefit carriers | Benefits early AD | Approval 2023 [@van2023] |
| Donanemab | N-terminal Aβ | Limited data | Benefits early AD | Approval 2024 [@sims2023] |
| Aduanumab | Aβ plaques | Limited data | Controversial efficacy | Withdrawn 2024 |
| Gantenerumab | Aβ plaques | Trial ongoing | Trial ongoing | GRADUATE trial |
Response in FAD:
| Treatment | FAD | LOAD |
|-----------|-----|------|
| Cholinesterase inhibitors | Effective | Effective |
| Memantine | Effective | Effective |
| Antidepressants | May worsen | May help |
| Antipsychotics | Higher risk | High risk |
FAD Trials:
| Feature | Familial AD | Sporadic AD |
|---------|-------------|--------------|
| First symptom | Memory (typical) | Memory (typical) or other |
| Language | May be early (PSEN1) | Often later |
| Visuospatial | Variable | Often early |
| Executive | Variable | Often early |
| Behavioral | Often later | Often early |
| Feature | FAD | LOAD |
|---------|-----|------|
| Myoclonus | Common (PSEN1) | Less common |
| Seizures | More common | Less common |
| Movement disorder | May occur | Less common |
| Psychiatric | Variable | Depression common early |
| Autonomic | Variable | Often prominent |
| Measure | FAD | LOAD |
|---------|-----|------|
| Mean survival | 8-10 years | 8-12 years |
| Range | 4-20 years | 4-20 years |
| From onset to death | Shorter with earlier onset | More variable |
Familial AD:
| Scenario | Recommended Testing |
|----------|---------------------|
| Early onset (<60 years) | PSEN1, PSEN2, APP sequencing |
| Family history (autosomal dominant) | Targeted gene panel |
| LOAD risk assessment | APOE (limited utility) |
| Research | Multi-gene panels, GWAS |
FAD-Specific: